<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383380</url>
  </required_header>
  <id_info>
    <org_study_id>RTAPDS</org_study_id>
    <nct_id>NCT03383380</nct_id>
  </id_info>
  <brief_title>Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome</brief_title>
  <official_title>Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin
      therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described autosomal
      dominant primary immunodeficiency (PID), caused by the mutations in PIK3CD gene. The
      manifestations of APDS mainly include recurrent respiratory tract infections, persistent
      Epstein-Barr virus (EBV)/ cytomegalovirus (CMV)infections, lymphadenopathy, splenomegaly,
      CD4+T cells lymphopenia, and hyper-IgM syndrome. PIK3CD encodes p110δ, the catalytic subunit
      of phosphatidylinositol 3-kinase (PI3K) which mainly expresses in leukocytes, being critical
      for their proliferation, activation and survival. Gain-of-function (GOF) PIK3CD mutations
      lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mammilian target of
      rapamycin (mTOR) hyperphosphorylated. Patient-derived lymphocytes had increased levels of
      phosphatidylinositol 3,4,5-trisphosphate and phosphorylated AKT protein. Hyperactivation of
      mTOR increases phosphorylation of kinases and increased glycolysis that results in enhanced
      proliferation and senescence of terminally differentiated CD8+ Tcell populations.

      The optimal treatment for these APDS patients is not yet determined; however, there are many
      kinds of therapeutic approaches (anti-infection prophylaxis, immunoglobulin replacement,
      conventional immunosuppressants, PI3K/mTOR inhibitors and hematopoietic stem cell
      transplantation). The APDS patients frequently receive treatment with immunoglobulin
      replacement and antibiotics. Hematopoietic stem cell transplantation (HSCT) has been
      currently curative in APDS patients; however, longer-term follow-up to determine the degree
      of donor chimerism and efficacy is required. There are several subjects without a prompt
      suitable matched donor or for whom the critical disease conditions force to postpone HSCT.The
      mammalian/mechanistic target of inhibitor rapamycin was reported to improve circulating
      T-cell profiles. Individual patients in previous studies experienced a decrease in
      nonneoplastic lymphoproliferation while taking rapamycin.

      The investigators in this study hope to evaluate the efficacy and safety of rapamycin in the
      treatment for carefully selected patients with APDS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Recurrent Infections</measure>
    <time_frame>5 years</time_frame>
    <description>Frequency of recurrent infections of the patients as indicators of rapamycin efficacy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatosplenomegaly</measure>
    <time_frame>5 years</time_frame>
    <description>Changes in hepatosplenomegaly with rapamycin treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte subset</measure>
    <time_frame>5 years</time_frame>
    <description>The changes of lymphocytes subset were evaluated by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Unexpected toxic adverse events during and after using rapamycin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Activated PI3K-delta Syndrome</condition>
  <condition>Immunodeficiency Primary</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for patients with activated phosphoinositide 3-kinase δ syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with activated phosphoinositide 3-kinase δ syndrome

          2. No more than 18 years old

        Exclusion Criteria:

          1. Patients with serious fungous infection

          2. Patients with serious complications

          3. Lack of parental consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinqiao Sun, Ph.D.,M.D</last_name>
    <phone>86-21-64932909</phone>
    <email>jinqiaosun@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weili Yan, Ph.D.</last_name>
    <phone>86-21-64931913</phone>
    <email>yanwl@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Yan, Ph.D</last_name>
      <email>yanwl@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16.</citation>
    <PMID>27555459</PMID>
  </reference>
  <reference>
    <citation>Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M, Stoddard J, Ouyang W, Frucht DM, Rao VK, Atkinson TP, Agharahimi A, Hussey AA, Folio LR, Olivier KN, Fleisher TA, Pittaluga S, Holland SM, Cohen JI, Oliveira JB, Tangye SG, Schwartzberg PL, Lenardo MJ, Uzel G. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014 Jan;15(1):88-97. doi: 10.1038/ni.2771. Epub 2013 Oct 28.</citation>
    <PMID>24165795</PMID>
  </reference>
  <reference>
    <citation>Tsujita Y, Mitsui-Sekinaka K, Imai K, Yeh TW, Mitsuiki N, Asano T, Ohnishi H, Kato Z, Sekinaka Y, Zaha K, Kato T, Okano T, Takashima T, Kobayashi K, Kimura M, Kunitsu T, Maruo Y, Kanegane H, Takagi M, Yoshida K, Okuno Y, Muramatsu H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Kojima S, Ogawa S, Ohara O, Okada S, Kobayashi M, Morio T, Nonoyama S. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency. J Allergy Clin Immunol. 2016 Dec;138(6):1672-1680.e10. doi: 10.1016/j.jaci.2016.03.055. Epub 2016 Jul 14.</citation>
    <PMID>27426521</PMID>
  </reference>
  <reference>
    <citation>Vignesh P, Rawat A, Singh S. An Update on the Use of Immunomodulators in Primary Immunodeficiencies. Clin Rev Allergy Immunol. 2017 Apr;52(2):287-303. doi: 10.1007/s12016-016-8591-2. Review.</citation>
    <PMID>27873163</PMID>
  </reference>
  <reference>
    <citation>Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O, Smyth D, Maes M, Fiddler C, Juss J, Cilliers D, Markelj G, Chandra A, Farmer G, Kielkowska A, Clark J, Kracker S, Debré M, Picard C, Pellier I, Jabado N, Morris JA, Barcenas-Morales G, Fischer A, Stephens L, Hawkins P, Barrett JC, Abinun M, Clatworthy M, Durandy A, Doffinger R, Chilvers ER, Cant AJ, Kumararatne D, Okkenhaug K, Williams RL, Condliffe A, Nejentsev S. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013 Nov 15;342(6160):866-71. doi: 10.1126/science.1243292. Epub 2013 Oct 17.</citation>
    <PMID>24136356</PMID>
  </reference>
  <reference>
    <citation>Walsh CM, Fruman DA. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. J Clin Invest. 2014 Sep;124(9):3688-90. doi: 10.1172/JCI77198. Epub 2014 Aug 18.</citation>
    <PMID>25133419</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Jinqiao Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Activated PI3K-delta Syndrome</keyword>
  <keyword>Immunodeficiency Primary</keyword>
  <keyword>Akt/mTOR pathway</keyword>
  <keyword>Rapamycin Therapy</keyword>
  <keyword>Hyperphosphorylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

